Status:
COMPLETED
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis
Lead Sponsor:
Xijing Hospital
Conditions:
Autoimmune Encephalitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Autoimmune encephalitis (AE) is an immune-mediated brain disorder characterized by varied clinical manifestations that correlate with specific types of antibodies.Typical symptoms include acute behavi...
Eligibility Criteria
Inclusion
- Diagnosis of definite autoimmune encephalitis(Graus et al 2016.)
- Age ≥ 18 years
- Acute or subacute onset (rapid progression of less than 3 months)
- Reasonable exclusion of alternative causes
- Written informed consent
Exclusion
- Known allergy to tetracycline antibiotics.
- Pregnant women.
- Uncontrolled serious concomitant illness.
- Known chronic kidney disease stages 3b-5.
- Moderate liver disease (see Child-Pugh for Classification of Severity of Liver Disease).
- history of cognitive impairment
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 16 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06033846
Start Date
October 1 2023
End Date
July 16 2025
Last Update
August 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hospital
Xi'an, China